Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Share-based Compensation (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Share-based Compensation data on record, last reported at $18.5 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 7.42% year-over-year to $18.5 million; the TTM value through Dec 2025 reached $74.5 million, changed 0.09%, while the annual FY2025 figure was $74.5 million, 0.09% changed from the prior year.
  • Share-based Compensation reached $18.5 million in Q4 2025 per PTCT's latest filing, down from $19.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $29.4 million in Q2 2023 and bottomed at $17.2 million in Q4 2024.
  • Average Share-based Compensation over 5 years is $23.6 million, with a median of $25.7 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: surged 68.9% in 2021, then tumbled 36.22% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $26.2 million in 2021, then rose by 4.22% to $27.3 million in 2022, then decreased by 1.47% to $26.9 million in 2023, then tumbled by 36.01% to $17.2 million in 2024, then rose by 7.42% to $18.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $18.5 million in Q4 2025, $19.4 million in Q3 2025, and $18.5 million in Q2 2025.